No Data
No Data
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.
Aura Biosciences | 10-K/A: Annual report (Amendment)
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Collplant Holdings (CLGN) and Zimmer Biomet Holdings (ZBH)
Aura Biosciences to Host Virtual KOL Event "Pioneering a New Standard of Care In Ocular Oncology" on May 29, 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve
JMP Securities Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $19
JMP Securities analyst Jonathan Wolleben maintains $Aura Biosciences(AURA.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 42